Proceedings of the National Academy of Sciences · 2023 · 33 citations · 48 references
Life SciencesImmunologyInfectious DiseasesImmunotherapyMolecular VirologyVirologyAnimal VirusesAntiviral ImmunityAntiviral TherapyEmerging Viral DiseasesViral GeneticsViral InfectionsAdministration Of Monoclonal AntibodiesAntiviral ImmunotherapyMonoclonal Antibody InteractionsPrimate Infectious Diseases
There are no approved treatments for Lassa fever (LF), which is responsible for thousands of deaths each year in West Africa. A major challenge in developing effective medical countermeasures against LF is the high diversity of circulating Lassa virus (LASV) strains with four recognized lineages and four proposed lineages. The recent resurgence of LASV in Nigeria caused by genetically distinct strains underscores this concern. Two LASV lineages (II and III) are dominant in Nigeria. Here, we show that combinations of two or three pan-lineage neutralizing human monoclonal antibodies (8.9F, 12.1F, 37.D) known as Arevirumab-2 or Arevirumab-3 can protect up to 100% of cynomolgus macaques against challenge with both lineage II and III LASV isolates when treatment is initiated at advanced stages of disease on day 8 after LASV exposure. This work demonstrates that it may be possible to develop postexposure interventions that can broadly protect against most strains of LASV.
48
Joseph B. McCormick, I. J. King, P. A. Webb et al. · New England Journal of Medicine · 1986 · 997 citations
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17
Genetic Diversity among Lassa Virus Strains
Michael D. Bowen, Pierre E. Rollin, Thomas G. Ksiazek et al. · Journal of Virology · 2000 · 326 citations